315 related articles for article (PubMed ID: 26238069)
1. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
2. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
3. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Yuan H; Chen J; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2015 Oct; 21(19):4365-72. PubMed ID: 25979484
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
5. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
[TBL] [Abstract][Full Text] [Related]
7. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
8. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
9. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Sheng S; Xu Y; Guo Y; Yao L; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jan; 146(2):487-495. PubMed ID: 31119730
[TBL] [Abstract][Full Text] [Related]
11. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Mombelli S; Kwiatkowski F; Abrial C; Wang-Lopez Q; de Boissieu P; Garbar C; Bensussan A; Curé H
Oncology; 2015; 88(5):261-72. PubMed ID: 25573741
[TBL] [Abstract][Full Text] [Related]
15. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
[TBL] [Abstract][Full Text] [Related]
17. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
[TBL] [Abstract][Full Text] [Related]
18. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
19. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Tibau A; López-Vilaró L; Pérez-Olabarria M; Vázquez T; Pons C; Gich I; Alonso C; Ojeda B; Ramón y Cajal T; Lerma E; Barnadas A; Escuin D
Neoplasia; 2014 Oct; 16(10):861-7. PubMed ID: 25379022
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients.
Wu L; Yao L; Zhang H; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Yin CC; Xie Y
Oncotarget; 2016 Jan; 7(4):5042-52. PubMed ID: 26573232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]